Clinical Trial Update: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating MT-7117 in erythropoietic protoporphyria and X-linked protoporphyria has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria
• X-linked Protoporphyria

Drugs mentioned

• MT-7117

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: EPP, XLP | Phase 3 | Status: COMPLETED | Results posted: 2025-03-21